Please assess the completion status of the following clinical trial:

Trial Title: Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for Mothers:~* HIV-infected~* At least at 26th week of pregnancy (treatment group) or 18th week of pregnancy (observational group) but not beyond the 34th week of pregnancy~* Able to complete study visits until at least 6 months postpartum~* Citizen of Botswana~Exclusion Criteria for Mothers:~* Taken ARVs for more than 1 week, other than ZDV, during current or prior pregnancy. Women who have received single-dose NVP in a prior pregnancy are not excluded.~* Certain abnormal laboratory values~* Plan to formula feed~* Known fetal abnormalities that suggest the fetus will not survive to 6 months of gestational age~* Known allergy or medical contraindication to any of the study drugs~* Require certain medications~* Previous participation in the Prevention of Milk-Borne Transmission of HIV-1C in Botswana (Mashi) study~* Currently incarcerated

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Trizivir (TZV) Arm (Type: EXPERIMENTAL): Participants in the TZV Arm (Arm 1A) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
- Kaletra Arm (Type: EXPERIMENTAL): Participants in the Kaletra Arm (Arm 1B) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive Lamivudine/Zidovudine (3TC/ZDV) and Lopinavir/Ritonavir (LPV/RTV) twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
- Nevirapine (NVP) Arm (Type: EXPERIMENTAL): Participants in the NVP Arm (Arm 2) will be pregnant women who have have CD4 counts less than 200 cells/mm3. These participants will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.

Based on this trial design, predict the completion outcome and termination type (if applicable).